ABBV · News · 20260917N

Product / Drug Pipeline Progress

AbbVie Inc. · 2026-09-17 · Importance 31 · Surprise 42

AbbVie said Phase 3 CERVINO results for etentamig met the dual primary endpoints of objective response rate and progression-free survival in relapsed/refractory multiple myeloma. The company will present the data at the International Myeloma Society Annual Meeting in Glasgow, Scotland, on September 23–26, 2026. Additional data will cover ABBV-2001 (ISB 2001), surzetoclax, and combination approaches, supporting AbbVie's strategy to build a multiple myeloma portfolio across complementary mechanisms.